

GLAXOSMITHKLINE PLC
Form 6-K
April 11, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 11 April 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares under the Company's ShareReward Plan
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.4378	8 (partnership shares)
£16.4378	8 (matching shares)
 - d) Aggregated information
Aggregated volume Price 16 Ordinary Shares
£16.4378
 - e) Date of the transaction 2017-04-11
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Manufacturing & Supply
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
 where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each
 ('Ordinary Shares')
- b) Nature of the transaction ISIN: GB0009252882
 Acquisition of Ordinary Shares
 under the Company's ShareReward
 Plan
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|------------------------|
| £16.4378 | 8 (partnership shares) |
| £16.4378 | 8 (matching shares) |
- d) Aggregated information
 Aggregated volume Price 16 Ordinary Shares
 £16.4378
- e) Date of the transaction 2017-04-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S Dingemans
- b) Position/status Chief Financial Officer
- c) Initial notification/
 amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
 where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each
 ('Ordinary Shares')
- b) Nature of the transaction ISIN: GB0009252882
 Acquisition of Ordinary Shares
 under the Company's ShareReward
 Plan
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|------------------------|
| £16.4378 | 8 (partnership shares) |
| £16.4378 | 8 (matching shares) |
- d) Aggregated information

Aggregated volume Price

16 Ordinary Shares
£16.4378

- e) Date of the transaction 2017-04-11
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr N Hirons
b) Position/status SVP, Global Ethics & Compliance
c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each
(‘Ordinary Shares’)
ISIN: GB0009252882
Acquisition of Ordinary Shares
under the Company's ShareReward
Plan
b) Nature of the transaction

- c) Price(s) and volume(s)
Price(s) Volume(s)
£16.4378 8 (partnership shares)
£16.4378 8 (matching shares)

Aggregated information

- d) Aggregated volume Price 16 Ordinary Shares
£16.4378
e) Date of the transaction 2017-04-11
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr S A Hussain
b) Position/status President, Global Pharmaceuticals
c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's ShareReward Plan
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.4378	8 (partnership shares)
£16.4378	8 (matching shares)
 - d) Aggregated information

Aggregated volume	16 Ordinary Shares
Price	£16.4378
 - e) Date of the transaction 2017-04-11
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D S Redfern
 - b) Position/status Chief Strategy Officer
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's ShareReward Plan
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.4378	8 (partnership shares)
£16.4378	8 (matching shares)

Aggregated information

- d) Aggregated volume Price 16 Ordinary Shares
£16.4378
- e) Date of the transaction 2017-04-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares under the Company's ShareReward Plan
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|------------------------|
| £16.4378 | 8 (partnership shares) |
| £16.4378 | 8 (matching shares) |

Aggregated information

- d) Aggregated volume Price 16 Ordinary Shares
£16.4378
- e) Date of the transaction 2017-04-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status President, Global Affairs
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's ShareReward Plan
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|------------------------|
| £16.4378 | 8 (partnership shares) |
| £16.4378 | 8 (matching shares) |
- d) Aggregated information
- | Aggregated volume | Price |
|--------------------|----------|
| 16 Ordinary Shares | £16.4378 |
- e) Date of the transaction 2017-04-11
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr P J T Vallance
- b) Position/status President, R&D
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- b) Nature of the transaction

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Acquisition of Ordinary Shares
under the Company's ShareReward
Plan

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.4378	8 (partnership shares)
	£16.4378	8 (matching shares)

Aggregated information

d) Aggregated volume Price	16 Ordinary Shares
	£16.4378
e) Date of the transaction	2017-04-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mrs V A Whyte
b) Position/status	Company Secretary
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's ShareReward Plan

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.4378	8 (partnership shares)
	£16.4378	8 (matching shares)

Aggregated information

d) Aggregated volume Price	16 Ordinary Shares
	£16.4378
e) Date of the transaction	2017-04-11

f) Place of the transaction

London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 11, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc